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Epidemiology and incidence statistics
Lung cancer is the most common form of cancer in the world
(12.3% of all cancers), with an estimated 1.2 million new cases
in 2000 (Parkin et al., 2001). Tobacco smoking is the most
important cause of lung cancers with 80%–90% arising in ciga-
rette smokers (Figure 1). There are major geographic, racial,
and gender differences in incidence and some reports suggest
that women may be at increased risk of lung cancer from expo-
sure to tobacco smoke carcinogens. A lifetime smoker has a 20-
to 30-fold increased risk of developing lung cancer compared to
a lifetime nonsmoker. While smoking prevalence is decreasing
in the USA, in China and Eastern Europe, there is an epidemic
of smoking which will result in tens of millions of new cases in
this century (Parkin et al., 2001; Peto et al., 1999, 2000). Thus,
lung cancer is the most preventable of all cancers, and smoking
cessation results in decreased risk after a lag period of 7
years (Peto et al., 1999). However, this decreased risk never
reaches baseline levels, and lung cancer in the USA is becom-
ing a disease of former smokers. Despite improvements in ther-
apy, 90% of lung cancer patients will die from their disease. In
2000, it is estimated that lung cancer resulted in 1.1 million
deaths worldwide, or 17.8% of all cancer deaths. However, only
11% of heavy cigarette smokers ultimately develop lung can-
cer, suggesting that there may be genetic factors predisposing
to lung cancer risk (Lippman and Spitz, 2001).
Genetic epidemiology
Segregation studies indicate a 2.5-fold risk of lung cancer from
family history after controlling for cigarette smoking, suggesting
the presence of a rare autosomal dominant gene predisposing
to lung cancer (Amos et al, 1999). The familial association is
most readily detected in lung cancer occurring in nonsmokers.
However, the majority of inherited lung cancer risk probably
comes from small but significant effects arising from genetic
polymorphisms that are frequent in the population (Amos et al,
1999). Tobacco smoke contains over 20 known lung cancer-
specific carcinogens, especially the polycyclic aromatic hydro-
carbons and the tobacco-specific nitrosamine 4-(methylni-
trosamino)-1-(3-pyridyl)-1-butanone (NNK). Polymorphisms
that reduce the activity of the glutathione-S transferase family,
which inactivates the carcinogens, or that increase the activity
of the P450 family, which activates them, may result in
increased cancer susceptibility. The activated carcinogens bind
to DNA, forming adducts, leading to mutations, especially G-to-
T transversions, which may be repaired, lead to apoptosis, or
persist.Molecular epidemiology has shown differences in smok-
ing-related risk based on the interactions between tobacco car-
cinogens, genetic polymorphisms involved in activating and
detoxifying these carcinogens, and host cell efficiency in moni-
toring and repairing tobacco carcinogen-DNA damage (Fong et
al., 2001).
Conventional diagnostics and therapeutics
The majority of lung cancer cases are diagnosed when a symp-
tom appears related to the primary, metastatic disease, or para-
neoplastic syndrome (Minna, 2000). The evaluation of the lung
cancer patient involves obtaining material for a histologic diag-
nosis, determining the stage of the disease based on the
International TNM staging system using standard physical
examination, computed tomography (CT) scans of the chest
and abdomen, pulmonary function tests, routine laboratory
tests, and weight loss of the patient. Often a flexible fiberoptic
bronchoscopy is performed to directly look at the large airways
and obtain biopsy material, and a CT guided fine needle biopsy
is often performed.
Four major histologic types comprise the majority of lung
cancers, and include small cell lung cancer (SCLC) and the
three non-small cell lung cancer (NSCLC) types. Squamous
and SCLC arise mainly from the central airways, while adeno-
carcinomas (including bronchioloalveolar cancer) are peripher-
ally located. Large cell lung cancer represents less differentiat-
Figure 1. Nicotine addiction, tobacco smoke
carcinogens, and the pathogenesis of lung
carcinomas
Nicotine addiction is the powerful engine that
prevents smokers from quitting. The many lung
cancer-specific carcinogens (including poly-
cyclic aromatic hydrocarbons and nitro-
samines) in the particulate matter of tobacco
smoke have to be metabolized before they are
either secreted or can bind to DNA with the for-
mation of adducts. DNA adducts may be
repaired or lead to apoptosis. If they persist,
miscoding mutations in key genes such as P53
or RAS may cause genetic instability, leading to
further mutational damage and eventually to
cancer. Modified from Hecht (1999).
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ed forms of the other NSCLC types. There is no squamous
epithelium in the normal lung, and these tumors arise from
metaplastic changes resulting from smoking. SCLCs have neu-
roendocrine features and arise from cells programmed to differ-
entiate along these lines. Adenocarcinomas arise from the
progenitor cells of the bronchioles (Clara cells) or alveoli (Type II
pneumocytes) or from mucin producing cells. Adenocarcinoma
is the most common form of lung cancer in the world today, and
its frequency is increasing rapidly. It is by far the commonest
form in women, never smokers and in young people.
Patients with SCLC with disease confined to the chest
(“limited stage”) receive concurrent chest radiotherapy and
chemotherapy that often includes cisplatin and etoposide
while those with more “extensive stage” disease receive
chemotherapy alone with drug combinations such as cis-
platin, etoposide, irinotecan, topotecan, or paclitaxel. These
treatments lead to long-term survival and potential cure in
10%–25% of limited stage patients and a few extensive stage
patients, while nearly all of patients have their tumors shrink
with therapy, gain symptom relieve, and an increase in medi-
an survival of 10–16 months (Minna, 2000).
NSCLC patients with disease confined to the chest are
further staged by surgical evaluation of the mediastinum for
lymph node involvement (and more recently by positron emis-
sion tomography “PET” scans). Those patients without evi-
dence of mediastinal lymph node involvement or distant
metastatic disease have a surgical resection of the primary
tumor (involving a lobe of the lung or the entire lung). For
those patients with mediastinal lymph node involvement
either preoperative chemotherapy (“neoadjuvant chemother-
apy”) followed by an attempt at surgical resection or a combi-
nation of chemotherapy and chest radiotherapy is given in a
curative approach. Alternatively, high dose radiotherapy to
the chest is given with curative intent. Depending on the stage
of the disease, surgical based approaches result in long-term
disease free survival and potential cure of 30%–50% of
resected patients. Unfortunately, the majority of patients end
up having distant metastatic disease. Currently available
chemotherapy agents for the treatment of NSCLC include
doublet combinations of cisplatin or carboplatin, and etopo-
side, gemcitabine, paclitaxel, docetaxel, vinorelbine, and
irinotecan (Bunn, 2001). These combinations produce 1-year
survival rates of about 35% and 2-year survival rates of about
15% (Bunn, 2001). While these therapies are not curative
they often result in symptom relief and prolongation of life in
the order of 2–10 months. Any patient not controlled by
chemotherapy is a candidate for local radiation therapy to
relieve symptoms.
Key genes and pathways involved in the
pathogenesis of lung cancer
Oncogenes that contribute to the pathogenesis of lung cancer
include c-myc, mutated K-ras (15%–20% of NSCLC, predomi-
nantly adenocarcinomas but never in SCLC) and overex-
pressed EGFR, cyclin D1, and BCL2 (Fong et al., 2001).
Telomerase RNA (hTR) and the catalytic component (hTERT)
are expressed in nearly all lung cancers providing a mechanism
for cellular immortality. Tumor suppressor genes (TSGs) fre-
quently involved include p53 (~90% of SCLC; 50% NSCLC), Rb
(~90% SCLC; ~20% NSCLC), and p16 (>50% NSCLC; <1%
SCLC). Abnormalities in the function of FHIT, RASFF1A, and
SEMA3B are implicated in the pathogenesis of a number of
lung cancers (Zochbauer-Muller et al., 2002), irrespective of
their controversial label as TSGs. Other TSGs that are less fre-
quently involved but whose occasional inactivation points to
involvement of their associated cell regulatory pathways include
PTEN, hOGG1 (DNA repair), BAP1 (ubiquination). The major
mode of inactivation of expression of many genes (APC,
CDH13, RARβ, FHIT, RASSF1A, TIMP3, p16, MGMT,
SEMA3B, DAPK) involves tumor-acquired promoter hyperme-
thylation (Belinsky et al., 1998; Zochbauer-Muller et al., 2001).
The methylated sequences can be detected in tumors, smoking
damaged normal lung (preneoplastic changes), sputum, and
blood (Zochbauer-Muller et al., 2001). These represent attrac-
tive surrogate biomarkers for early detection and monitoring
chemoprevention, smoking cessation and response to therapy.
Mitochondrial DNA, especially the displacement (D) loop, also
undergoes mutations, in lung cancer, but the functional signifi-
cance of this is unknown. The cell regulatory pathways that are
deregulated in lung cancer include the Rb/p16/cyclin D1,
p53/MDM2/p19ARF, wnt/APC, EGFR/Ras, PP2a, and telomer-
ase pathways, as well as several genes involved in various DNA
repair pathways. In addition, there is evidence of deregulation of
apoptosis, angiogenesis, autocrine/paracrine growth factor cir-
cuits. The methylation changes (epigenetic alterations) and
genome wide allelotyping changes showing allele loss (genetic
alterations) are starting to provide speculative estimates for the
minimal number of events (20–30) leading to the development
Figure 2. Progressive morphological and molec-
ular changes during the multistage develop-
ment of squamous cell lung carcinomas
Progressive allelic losses at the short arm of chro-
mosome 3 (3p) are illustrated. Each panel repre-
sents a resected squamous cell carcinoma. All
of the preinvasive lesions were identified and
carefully microdissected and analyzed for loss at
different 3p loci using multiple polymorphic
markers. Losses at some sites (such as 3p21)
occur early, while losses at other sites (such as
3p12) occur late (Wistuba et al., 1999). The lesion
at which the earliest allelic loss occurred for
each of the markers in each case is identified. L
=  lymphocytes (a source of constitutional DNA);
N = histologically normal epithelium; H = hyper-
plasia; D = dysplasia; C = carcinoma in situ; T =
invasive tumor. We thank Ivan Wistuba for assis-
tance in preparation of the figure.
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of clinically evident lung cancer (Zochbauer-Muller, 2001;
Girard, 2000). Many of the changes are common between
NSCLC and SCLC while others have a predominance for one or
the other.
Molecular abnormalities in smoking-damaged lung
as preneoplastic lesions
Lung cancers arise after a series of molecular and morphologi-
cal events. The molecular events commence in histologically
normal epithelium and show a specific sequence (Hirsch et al.,
2001). Precise microscopic based microdissection of epithelial
tissue followed by allelotyping of smoking damaged lung from
lung cancer patients or current or former smokers without lung
cancer revealed hundreds of thousands of lesions (90,000
cells in size) containing clonal abnormalities of allele loss (“a
field defect”), occurring in both histologically normal as well as
abnormal (e.g., hyperplasia, dysplasia, or carcinoma in situ;
Figures 2) respiratory epithelium (Park et al., 1999).While these
changes are found in the lungs of current and former smokers
without lung cancer they are almost never found in life time
never smokers (Wistuba et al., 1997). These clonal changes
persist for decades after smoking cessation (Wistuba et al.,
1997). There is a preferred order of these allele loss changes
with 3p allele loss (several 3p sites) followed by 9p (p16 locus)
as the earliest changes occurring in histologically normal
epithelium (Wistuba et al., 1997, 1999, 2000). Similar evidence
exists for multiple promoter methylation changes in smoking
damaged lung and sputum (Zochbauer-Muller et al., 2001).
Considerable attention has been given to the identification of
the 3p genes involved in lung cancer pathogenesis including
RARβ at 3p24, FHIT at 3p14.2, RASSF1A, FUS1, and SEMA3B
located together at 3p21.3, and potentially ROBO1 at 3p12
(Wistuba et al., 2000; Damman et al., 2000; Burbee et al., 2001;
Tomizawa et al., 2001; Zochbauer-Muller et al., 2002). Their
expression is frequently lost in lung cancer, usually by promoter
methylation.
Recent advances in diagnosis, treatment, and prevention
Spiral computed tomography scans for early detection
of lung cancer
CT (computed tomography) scans have been routinely used in
the staging of lung cancer patients. Recently there has been
intense interest generated in using low dose spiral (also called
helical) computed tomography scans to screen asymptomatic
patients with a history of cigarette smoking for the early detec-
tion of lung cancer (Henschke et al., 1999). The spiral CT
screening trials conducted primarily in the USA and Japan have
not yet been evaluated in randomized clinical trials but detected
30 lung cancers per 1000 patients undergoing an initial
screen. Nearly 85% of these tumors were very early stage
NSCLCs (usually adenocarcinomas) (stage I) and presumably
will have a very high rate of cure by surgery alone. Debate has
ensued over whether these cancers represent “over-diagnosis”;
that is tumors that would never grow to kill the patient, and thus
whether prospective randomized trials should be conducted.
Autofluorescence bronchoscopy, when used as an adjunct to
standard white light bronchoscopy, enhances the broncho-
scopist’s ability to localize small preneoplastic and neoplastic
lesions (Figure 3) (Lam et al., 1998).
PET (positron emission tomography) scans for improved
staging of lung cancer
A major advance in lung cancer staging has been the introduc-
tion of 18F-2-fluoro-2-deoxyglucose (FDG) positron emission
tomography (PET) (Pieterman et al., 2000). FDG PET imaging
uses the increased accumulation of FDG in tumor cells com-
pared to normal cells to identify malignant lesions and is 95%
sensitive and 85% specific. PET is useful for detection of both
mediastinal and distant metastatic disease and whole body
PET scans frequently detect unsuspected distant metastatic
disease or show other lesions to be benign resulting in clinical
management changes in up to 40% of patients. PET is also
used in evaluating solitary pulmonary nodules and can docu-
ment responses to chemotherapy in a matter of days.
Molecularly targeted therapies
New systemic therapies directed against rational targets have
entered clinical trials for the treatment of lung and other cancers
(Gibbs, 2000). They include angiogenesis inhibitors, epidermal
growth factor receptor (EGFR) inhibitors, HER2/neu receptor
inhibitors and other tyrosine kinase inhibitors, inhibitors of Ras
activation and function (such as farnesyltransferase inhibitors),
matrix metalloproteinase inhibitors, cyclin dependent kinase
inhibitors, inhibitors of autocrine and paracrine growth factor
loops, anti-sense molecules such as those directed against
BCL2 or PKCα, vaccines against tumor mutated or specifically
expressed peptides, and gene replacement therapy. While cur-
rently available chemotherapy has beneficial effects, often this
is small. Recently, this rationally targeted approach has been
greatly stimulated by the clinical success of BCR/Abl and c-kit
inhibitors in chronic myelogenous leukemia and gastrointestinal
stromal tumors.
Prevention of lung cancer
The primary prevention of lung cancer through the prevention of
smoking initiation (particularly in children and young adults) and
helping people to stop smoking remains the long term key to
lung cancer control. There have been significant decreases in
Figure 3. Fluorescence bronchoscopy for the
identification of preinvasive and early invasive
lesions
Decreased autofluorescence may identify
preinvasive or early invasive lesions that con-
ventional white light bronchoscopy (left) failed
to identify. A small focus (less than 2 mm in size)
of decreased fluorescence (middle) is identified
in the spur of a major bronchus (as marked by
the dotted line; Lam et al., 1998). Biopsy of this
lesion (right) demonstrated moderate to severe
dysplasia. We thank Stephen Lam for providing
the images.
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smoking in certain segments of the population (such as in adult
white males) that have had effects in leveling off the increase in
lung cancer incidence.Whether there are gender differences in
response to tobacco carcinogens, in development of nicotine
addiction, or in expression of autocrine growth factor receptors
such as for gastrin releasing peptide is an important new area of
research. Trial proven aids for smoking cessation include the
involvement of physicians in patient counseling, psychological
support, nicotine replacement therapy, and the use of antide-
pressants (Fiore et al., 1997). Persons may also have inherited
differences in their susceptibility to nicotine and thus smoking
addiction.
Treatment of current and former smokers with agents
thought to block the progression of lung cancer pathogenesis
(chemoprevention) has been fraught with difficulty. There have
been definitive, randomized, controlled lung-cancer chemopre-
vention trials all of which produced negative (either neutral or
harmful) primary end point results (Lippman and Spitz, 2001).
Recently vitamin E and selenium were found to show promise
for lung cancer prevention, and there is interest in testing Cox-2
inhibition or the use of EGFR and farnysltransferase inhibitors.
Future challenges
The major challenges are: to develop social, cultural, and eco-
nomic approaches to deal with the tobacco epidemic; develop
new methods to prevent smoking initiation and to aid in smoking
cessation including understanding the genetic basis of nicotine
addiction; to develop new imaging, molecular genetic, and
genetic epidemiological methods for early detection and the
chemoprevention in lung cancer particularly in those individuals
who have altered their life styles by stopping cigarette smoking;
to be able to delineate all the significant molecular abnormali-
ties present in any one patient’s tumor and to use this informa-
tion for early molecular detection, prediction of biological/clinical
behavior and prognosis, and selection or rational development
of therapeutics.
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